Neuland Laboratories Ltd (NEULANDLAB) Q1 FY27 Results Analysis: Revenue Surges 119%, Margin Above Sustainable Band
Neuland Laboratories Ltd's Q1 FY27 numbers came in strong, with revenue of Rs. 641.58 Cr (+119.15% YoY) and PAT growth of +962.40% YoY. Here's a quick read of what worked, what to watch, and what management said.
| Results date | August 05, 2026 |
|---|---|
| Quarter | Q1 FY 2026-2027 |
| Revenue (Q1) | Rs. 641.58 Cr (+119.15% YoY) |
| PAT (Q1) | Rs. 147.67 Cr (+962.40% YoY) |
| EBITDA margin | 35.59% (+2150 bps YoY) |
| EPS (Q1) | Rs. 115.10 (+962.79% YoY) |
| Market cap | Rs. 25,582.96 Cr |
| CMP | Rs. 19,956.00 |
Quarter Snapshot
Neuland Laboratories reported a strong Q1 with revenue up 119% YoY to Rs.641.58 Cr and EBITDA margin of 35.59%, above its sustainable 25-30% band. The growth is driven by CDMO exports to Europe and USA, with export share rising to 87%. Capacity expansions at Unit 1 and a strategic collaboration with Gland Pharma support future growth. However, sequential revenue declined 17% from Q4's record, and India domestic API business contracted, highlighting lumpiness.
Key Investment Insights
Key Positives
- Revenue grew 119% YoY to Rs.641.58 Cr, the second-highest quarterly figure ever reported.
- EBITDA margin (management definition) came in at 35.59%, above the guided 25-30% sustainable band.
- PAT grew 962% YoY to Rs.147.67 Cr, with EPS at Rs.115.10.
- Europe revenue surged 221% YoY and USA revenue grew 204% YoY, driving the CDMO-led growth.
- Export revenue now constitutes 87% of total revenue, up from 66% in Q1FY26.
- Two capacity expansions at Unit 1 (total Rs.183.2 Cr) approved to address near-full utilization.
Risk Factors
- Revenue declined 17.35% QoQ from Q4 FY26's record Rs.776.25 Cr, consistent with management's warning about lumpy business.
- India revenue declined 15.83% YoY to Rs.83.26 Cr, indicating domestic generic API contraction.
- USA revenue declined 36.34% QoQ, reflecting lumpy shipment patterns in North America.
- Finance costs increased 52% YoY to Rs.6.97 Cr due to higher borrowings for capex.
Ask about this
Ask Cofacto a question about this result. Answers cite filings and company data.
Related
Disclaimer: This results analysis is published for educational and informational purposes only. It is not investment advice, not a recommendation to buy, sell or hold any security.